Interferon Beta-1A

Evidence Level: N/A

Predicted Indications: 0

---

Table of Contents

1. Interferon Beta-1A
   1. Pharmacist Assessment Report
   2. Interferon Beta-1A: Known uses and market status in India
   3. Summary
   4. Quick overview
   5. Known uses among the model’s candidates
      1. Approved (supported by a licence or label)
      2. Related to an approved indication (same disease category)
      3. Relations recorded in the knowledge graph (no approval found)
   6. India Market Information
   7. Safety Considerations
   8. Disclaimer

---

Pharmacist Assessment Report

Interferon Beta-1A: Known uses and market status in India

Summary

The TxGNN deep-learning model (score ≥ 0.99) produced candidates for Interferon Beta-1A, but every candidate that can be traced to a source is already a known use. There is therefore currently no new predicted indication for this drug. The one known use, relapsing-remitting multiple sclerosis, is supported by a licence in another country.

Quick overview

Item	Content
New predicted indications	None (all traceable model candidates are known uses)
Known uses among model candidates	1
Evidence level	Not applicable
India Market Status	Listed in a compiled Indian medicine price dataset (4 of 4) – CDSCO approval status is not included in this data
Number of Listed Products	4 (valid: 4)

Known uses among the model’s candidates

Approved (supported by a licence or label)

Indication	Source
relapsing-remitting multiple sclerosis	licence in another country (approved indication: multiple sclerosis)

Related to an approved indication (same disease category)

Indication	Approved category
none	none

Relations recorded in the knowledge graph (no approval found)

Indication
none

India Market Information

Licence	Product	Dosage form	Status
28723	Betaferon 250mcg Injection	vial of 1 Injection	Valid
188174	Rebif 44mcg Injection	vial of 1 Injection	Valid
3047	AVONEX 30 MCG INJECTION	vial of 1 Injection	Valid
187471	Relibeta Injection	prefilled syringe of 0.5 ml Injection	Valid

Safety Considerations

• Drug Interactions: 284 interactions were recorded. Among those listed, bupropion is rated Major. Examples rated Moderate include:
  • Antidiabetic agents: acarbose, pioglitazone, rosiglitazone
  • Statins: rosuvastatin, simvastatin
  • Anti-infectives: clarithromycin, levofloxacin, minocycline, clotrimazole
  • Anabolic steroids: oxandrolone, oxymetholone, stanozolol
  • Others: naltrexone, orlistat, nicotinamide, chenodeoxycholic acid, bowel-preparation agents

Please refer to the package insert for warnings and contraindications.

Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.

---